These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1388697)

  • 41. Human intestinal phenol sulfotransferase: assay conditions, activity levels and partial purification of the thermolabile form.
    Sundaram RS; Szumlanski C; Otterness D; van Loon JA; Weinshilboum RM
    Drug Metab Dispos; 1989; 17(3):255-64. PubMed ID: 2568905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat.
    Jones SR; Garris PA; Kilts CD; Wightman RM
    J Neurochem; 1995 Jun; 64(6):2581-9. PubMed ID: 7760038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human phenol sulfotransferase: correlation of brain and platelet activities.
    Young WF; Laws ER; Sharbrough FW; Weinshilboum RM
    J Neurochem; 1985 Apr; 44(4):1131-7. PubMed ID: 3855967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulfate conjugation of dopamine in rat brain: regional distribution of activity and evidence for neuronal localization.
    Rivett AJ; Francis A; Whittemore R; Roth JA
    J Neurochem; 1984 May; 42(5):1444-9. PubMed ID: 6584547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glutathione-related enzymes in brain in Parkinson's disease.
    Sian J; Dexter DT; Lees AJ; Daniel S; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):356-61. PubMed ID: 8080243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 48. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
    Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
    Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brain acetylcholinesterase in Parkinson's disease.
    Rinne UK; Riekkinen P; Sonninen V; Laaksonen H
    Acta Neurol Scand; 1973; 49(2):215-26. PubMed ID: 4718190
    [No Abstract]   [Full Text] [Related]  

  • 52. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
    Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form.
    Campbell NR; Van Loon JA; Weinshilboum RM
    Biochem Pharmacol; 1987 May; 36(9):1435-46. PubMed ID: 3472524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
    Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
    Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Neuroimage Clin; 2016; 10():54-62. PubMed ID: 26702396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.
    Riederer P; Sofic E; Rausch WD; Schmidt B; Reynolds GP; Jellinger K; Youdim MB
    J Neurochem; 1989 Feb; 52(2):515-20. PubMed ID: 2911028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.
    Gellhaar S; Sunnemark D; Eriksson H; Olson L; Galter D
    Cell Tissue Res; 2017 Sep; 369(3):445-454. PubMed ID: 28466093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.